<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993486</url>
  </required_header>
  <id_info>
    <org_study_id>CR-GVH-001</org_study_id>
    <nct_id>NCT00993486</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor</brief_title>
  <official_title>Phase I, Dose-ranging, Open-label, Study of a Single Administration of T-cells Add-back Depleted of Host Alloreactive Cells Using Theralux™ Therapy, Following Haploidentical Peripheral Blood Stem Cell Transplantation Submitted to CD34+ Cell Selection, in Patients With Severe Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiadis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiadis Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose and evaluate the safety
      of the administration of donor lymphocytes depleted of alloreactive T-cells following a stem
      cell transplant from a related, haploidentical donor, in patients with severe hematologic
      malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic stem cell transplantation is the treatment of choice for many patients with
      leukemia and other hematologic malignancies. However, a major limitation of this therapy is
      that for a significant number of patients no fully HLA-matched donor can be found. The
      application of partially HLA-matched (haploidentical) family donors, who are virtually always
      available, has some complications. If there is no T-cell add-back it increases the risk for
      life-threatening infections and disease relapse, while in case of T-cell add-back the risk of
      graft-versus-host disease is raised.

      Kiadis Pharma has developed a method to selectively deplete host alloreactive T-cells through
      photodynamic therapy, using TH9402 ex vivo. The donor lymphocyte preparation depleted of
      functional alloreactive T-cells (ATIR) are administered to the patient 4-6 weeks after the
      stem cell transplant. This method enables early immune reconstitution while preventing
      graft-versus-host disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity, defined as acute graft-versus-host disease grade III or IV</measure>
    <time_frame>Within 30 days after ATIR infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>Until 60 months after ATIR infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of disease relapse</measure>
    <time_frame>Until 60 months after ATIR infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and severity of graft-versus-host disease</measure>
    <time_frame>Until 60 months after ATIR infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse drug reactions</measure>
    <time_frame>Until 18 months after ATIR infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of infections</measure>
    <time_frame>Until 18 months after ATIR infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>L1 (dose 1.0x10E4 T-cells/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L2 (dose 5.0x10E4 T-cells/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L3 (dose 1.3x10E5 T-cells/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L4 (dose 3.2x10E5 T-cells/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L5 (dose 7.9x10E5 T-cells/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L6 (dose 2.0x10E6 T-cells/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L7 (dose 5.0x10E6 T-cells/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)</intervention_name>
    <description>Single intravenous infusion</description>
    <arm_group_label>L1 (dose 1.0x10E4 T-cells/kg)</arm_group_label>
    <arm_group_label>L2 (dose 5.0x10E4 T-cells/kg)</arm_group_label>
    <arm_group_label>L3 (dose 1.3x10E5 T-cells/kg)</arm_group_label>
    <arm_group_label>L4 (dose 3.2x10E5 T-cells/kg)</arm_group_label>
    <arm_group_label>L5 (dose 7.9x10E5 T-cells/kg)</arm_group_label>
    <arm_group_label>L6 (dose 2.0x10E6 T-cells/kg)</arm_group_label>
    <arm_group_label>L7 (dose 5.0x10E6 T-cells/kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any of the following hematologic malignancies: very high risk leukemia, acute
             leukemia, chronic myeloid leukemia (CML), lymphoma, multiple myeloma (MM),
             myelodysplastic syndrome (MDS)

          -  Incompatibility at two to three loci (HLA-A, B and/or DR) or a single DR locus of the
             unshared haplotype between the donor and recipient

          -  Life expectancy of at least 3 months

          -  Satisfactory performance status (ECOG ≤ 2);

        Exclusion Criteria:

          -  Possibility of performing an allogeneic transplant with an HLA (human leukocyte
             antigen) matched sibling donor

          -  Availability of an 6/6 HLA-A, B and DRB1 matched unrelated donor within 2-3 months;

          -  Pregnancy

          -  Viral hepatitis (B or C)

          -  Active serious infectious process

          -  HIV positivity;

          -  Systemic dysfunction (cardiac, pulmonary, hepatic and renal) contra-indicating
             allogeneic stem cell transplantation

          -  Prior allogeneic transplantation

          -  Prior autologous transplantation within twelve months of baseline visit

          -  Any abnormal condition or laboratory result that is considered by the principal
             investigator capable of altering patient condition or study outcome

          -  Active central nervous system (CNS) disease at baseline

          -  Participation in a trial with an investigational agent within 30 days prior to entry
             in the study

          -  Malignant cells in circulating peripheral blood (&gt; 25%)

          -  Other active malignant disease that would severely limit life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis-Claude Roy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital, Montréal, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2009</study_first_submitted>
  <study_first_submitted_qc>October 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2009</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haploidentical stem cell transplantation</keyword>
  <keyword>Graft-versus-host disease</keyword>
  <keyword>Immune reconstitution</keyword>
  <keyword>Alloreactive T-cells</keyword>
  <keyword>Photodepletion</keyword>
  <keyword>TH9402</keyword>
  <keyword>Transplant related mortality</keyword>
  <keyword>Hematologic malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

